FDA Dependence on User Fees Would Increase Under FY 2012 Budget Request
This article was originally published in The Pink Sheet Daily
Three new fees, including generic drug user fee, would help boost collections to $1.62 billion.
You may also be interested in...
OMB memo states that agencies should reduce net discretionary spending from the initial FY 2015 estimate and provide options for additional cuts.
Trigger changes could feed argument that user fees are a tax on industry.
FDA should spend $19 million of an increase in non-user fee funding in fiscal 2012 on the agency’s medical countermeasures effort, the Senate Appropriations Committee recommends in the report that accompanies the Agriculture/FDA appropriations bill approved by the panel Sept 8.